Correction: Tenofovir and emtricitabine-tenofovir preexposure prophylaxis for herpes simplex virus type 2 (Annals of Internal Medicine (2014) 161 (11-19) DOI: 10.7326/M13-2471);Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: A subgroup analysis of a randomized trial

Annals of Internal Medicine

Volumn 161, Issue 1, 2014, Pages 11-19

  Celum, Connie ^a   Morrow, Rhoda A ^a,b   Donnell, Deborah ^a   Hong, Ting ^a   Hendrix, Craig W ^a,c   Thomas, Katherine K ^a   Fife, Kenneth H ^a,d   Nakku Joloba, Edith ^a,e   Mujugira, Andrew ^a   Baeten, Jared M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b USA   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INDIANA UNIVERSITY   (United States)

^e MAKERERE UNIVERSITY   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; TENOFOVIR DISOPROXIL;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HAZARD RATIO; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HETEROSEXUAL FEMALE; HETEROSEXUAL MALE; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; KENYA; MALE; NEWBORN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; UGANDA;

ADENINE; ADMINISTRATION, ORAL; ADULT; ANTI-RETROVIRAL AGENTS; ANTIVIRAL AGENTS; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HETEROSEXUALITY; HIV INFECTIONS; HIV SERONEGATIVITY; HIV-1; HUMANS; INCIDENCE; MALE; MEDICATION ADHERENCE; ORGANOPHOSPHONATES; RNA, VIRAL;

EID: 84903555175     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/L16-0549     Document Type: Erratum

References (41)

1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-99. [PMID: 21091279]
2. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399-410. [PMID: 22784037]
3. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al Bangkok Tenofovir Study Group. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381:2083-90. [PMID: 23769234]
4. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al; TDF2 Study Group. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423-34. [PMID: 22784038]
5. Balzarini J, Holy A, Jindrich J, Naesens L, Snoeck R, Schols D, et al. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6- diaminopurine. Antimicrob Agents Chemother. 1993;37:332-8. [PMID: 8452366] (Pubitemid 23046579)
6. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al; CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168-74. [PMID: 20643915]
7. Tan D. Potential role of tenofovir vaginal gel for reduction of risk of herpes simplex virus in females. Int J Womens Health. 2012;4:341-50. [PMID: 22927765]
8. Centre for the AIDS Programme of Research in South Africa. Effectiveness & safety of vaginal microbicide 1% tenofovir gel for prevention of HIV infection in women. Congella, South Africa: Centre for the AIDS Programme of Research in South Africa; 2010. Accessed at www.conrad.org/media/news/92- CAPRISA%20004%20Results.pdf on 7 May 2014.
9. Karim SS, Kashuba AD, Werner L, Karim QA. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet. 2011;378:279-81. [PMID: 21763939]
10. Andrei G, Lisco A, Vanpouille C, Introini A, Balestra E, van den Oord J, et al. Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication. Cell Host Microbe. 2011;10:379-89. [PMID: 22018238]
11. Schwartz JL, Rountree W, Kashuba AD, Brache V, Creinin MD, Poindexter A, et al. A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. PLoS One. 2011;6: e25974. [PMID: 22039430]
12. Mujugira A, Baeten JM, Donnell D, Ndase P, Mugo NR, Barnes L, et al; Partners PrEP Study Team. Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PLoS One. 2011;6:e25828. [PMID: 21998703]
13. Lingappa J, Nakku-Joloba E, Magaret A, Friedrich D, Dragavon J, Kambugu F, et al. Sensitivity and specificity of herpes simplex virus-2 serological assays among HIV-infected and uninfected urban Ugandans. Int J STD AIDS. 2010;21:611-6. [PMID: 21097732]
14. Ashley RL, Militoni J, Lee F, Nahmias A, Corey L. Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol. 1988;26:662-7. [PMID: 2835389] (Pubitemid 18087189)
15. Keller MJ, Madan RP, Torres NM, Fazzari MJ, Cho S, Kalyoussef S, et al. A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS One. 2011;6:e16475. [PMID: 21283552]
16. Dropulic LK, Cohen JI. Update on new antivirals under development for the treatment of double-stranded DNA virus infections. Clin Pharmacol Ther. 2010; 88:610-9. [PMID: 20881959]
17. Prentice RL, Gloeckler LA. Regression analysis of grouped survival data with application to breast cancer data. Biometrics. 1978;34:57-67. [PMID: 630037] (Pubitemid 8316897)
18. Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11:561-70. [PMID: 10955409] (Pubitemid 30660035)
19. Breslow NE, Lumley T, Ballantyne CM, Chambless LE, Kulich M. Improved Horvitz-Thompson estimation of model parameters from two-phase stratified samples: applications in epidemiology. Stat Biosci. 2009;1:32. [PMID: 20174455]
20. Haberer JE, Baeten JM, Campbell J, Wangisi J, Katabira E, Ronald A, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med. 2013;10:e1001511. [PMID: 24058300]
21. Lumley T. Complex Surveys: A Guide to Analysis Using R. Hoboken, NJ: J Wiley; 2010.
22. Dumond JB, Yeh RF, Patterson KB, Corbett AH, Jung BH, Rezk NL, et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS. 2007;21:1899-907. [PMID: 17721097] (Pubitemid 47329766)
23. Lama J, Mayer K, Schechter M, Kallas E, Bekker LG, Chariyalertsak S, et al. Oral TDF and its impact in HSV-2 acquisition and clinical expression [Abstract]. Presented at the 18th Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, 27 February-2 March 2011. Abstract no. 1002.
24. Mesquita PM, Rastogi R, Segarra TJ, Teller RS, Torres NM, Huber AM, et al. Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection. J Antimicrob Chemother. 2012;67:1730-8. [PMID: 22467632]
25. Gatanaga H, Hayashida T, Tanuma J, Oka S. Prophylactic effect of antiretroviral therapy on hepatitis B virus infection. Clin Infect Dis. 2013;56:1812-9. [PMID: 23487374]
26. Price H, Dunn D, Pillay D, Bani-Sadr F, de Vries-Sluijs T, Jain MK, et al. Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis. PLoS One. 2013;8:e68152. [PMID: 23874527]
27. Soriano V, Poveda E, Vispo E, Barreiro P. Hepatitis B in HIV-infected patients. Clin Liver Dis. 2013;17:489-501. [PMID: 23905818]
28. Tan DH, Kaul R, Raboud JM, Walmsley SL. No impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding in HIV-infected adults. AIDS. 2011;25:207-10. [PMID: 21150556]
29. Muiru AN, Guthrie BL, Bosire R, Merkel M, Liu AY, Choi RY, et al. Incident HSV-2 infections are common among HIV-1-discordant couples. J Infect Dis. 2013;208:1093-101. [PMID: 23840044]
30. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS. 2006;20:73-83. [PMID: 16327322] (Pubitemid 41818117)
31. Martin ET, Krantz E, Gottlieb SL, Magaret AS, Langenberg A, Stanberry L, et al. A pooled analysis of the effect of condoms in preventing HSV-2 acquisition. Arch Intern Med. 2009;169:1233-40. [PMID: 19597073]
32. Hughes JP, Baeten JM, Lingappa JR, Magaret AS, Wald A, de Bruyn G, et al Partners in Prevention HSV/HIV Transmission Study Team. Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis. 2012;205:358-65. [PMID: 22241800]
33. Mahiane SG, Legeai C, Taljaard D, Latouche A, Puren A, Peillon A, et al. Transmission probabilities of HIV and herpes simplex virus type 2, effect of male circumcision and interaction: a longitudinal study in a township of South Africa. AIDS. 2009;23:377-383. [PMID: 19198042]
34. Tobian AA, Serwadda D, Quinn TC, Kigozi G, Gravitt PE, Laeyendecker O, et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med. 2009;360:1298-309. [PMID: 19321868]
35. Mehta SD, Moses S, Parker CB, Agot K, Maclean I, Bailey RC. Circumcision status and incident herpes simplex virus type 2 infection, genital ulcer disease, and HIV infection. AIDS. 2012;26:1141-9. [PMID: 22382150]
36. Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT, et al Herpevac Trial for Women. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med. 2012;366:34-43. [PMID: 22216840]
37. Johnston C, Koelle DM, Wald A. Current status and prospects for development of an HSV vaccine. Vaccine. 2014;32:1553-60. [PMID: 24016811]
38. Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T, et al Valacyclovir HSV Transmission Study Group. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med. 2004;350:11-20. [PMID: 14702423] (Pubitemid 38032179)
39. Mujugira A, Magaret AS, Celum C, Baeten JM, Lingappa JR, Morrow RA, et al Partners in Prevention HSV/HIV Transmission Study Team. Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial. J Infect Dis. 2013;208:1366-74. [PMID: 23901094]
40. Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delany-Moretlwe S, et al HPTN 039 Protocol Team. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371:2109-19. [PMID: 18572080] (Pubitemid 351902179)
41. Watson-Jones D, Weiss HA, Rusizoka M, Changalucha J, Baisley K, Mugeye K, et al; HSV trial team. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med. 2008;358:1560-71. [PMID: 18337596] (Pubitemid 351519816)